Showing 3451-3460 of 4164 results for "".
- Pr3vent Completes Series A Financing Led By InFocus Capital Partnershttps://modernod.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/Pr3vent, a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Tro
- GenSight’s Gene Therapy GS010 Fails Second Late-Stage Leber Hereditary Optic Neuropathy Studyhttps://modernod.com/news/gensights-gene-therapy-gs010-fails-second-late-stage-leber-hereditary-optic-neuropathy-study/2476321/GenSight Biologics announced that a phase 3 study investigating a single injection of the experimental gene therapy GS010 failed to improve vision loss compared to sham treatment in patients with 11778-ND4 Leber hereditary optic neuropathy (LHON). In the RESCUE study, patients with
- MacuLogix Hosts Inaugural AMD Speaker Alliancehttps://modernod.com/news/maculogix-hosts-inaugural-amd-speaker-alliance/2476336/MacuLogix hosted the industry’s first AMD Speaker Alliance meeting. The peer-to-peer event was attended by 25 optometric key opinion leaders who are at the front lines of minimizing vision loss due to AMD and other retinal disease. “This meeting is helping us kick off a movement in our pro
- Bausch + Lomb Introduces Zen Multifocal Scleral Lens for Presbyopiahttps://modernod.com/news/bausch-lomb-introduces-zen-multifocal-scleral-lens-for-presbyopia/2476173/Bausch + Lomb announced the introduction of the Zen multifocal scleral lens for presbyopia, which will be exclusively available with Zenlens and Zen RC scleral lenses through the company’s specialty vision products unit. This innovation will allow eye care professionals to fit presbyopic patients
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- AMD Monitoring Comes Home: The Promise of Innovative Remote Techhttps://modernod.com/news/amd-monitoring-comes-home-the-promise-of-innovative-remote-tech/2476239/Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, or the central part of the retina, which has the highest density of photoreceptors, allowing for high-resolution central visual acuity. An e
- Spark Therapeutics Gene Therapy Pioneers Win $1 Million Sanford Lorraine Cross Awardhttps://modernod.com/news/spark-therapeutics-gene-therapy-pioneers-win-1-million-sanford-lorraine-cross-award/2476159/Two women with a vision to make the blind see were the winners of the inaugural $1 million Sanford Lorraine Cross Award. Jean Bennett, MD, PhD, and Katherine A. High, MD, whose work with the RPE65 mutation has reversed an inherited form of blindness, accepted the award on December 4 at Sanford He
- Two Studies Measure Performance of Acuvue Oasys with Transitions Light Intelligent Technology Contact Lenseshttps://modernod.com/news/two-studies-measure-performance-of-acuvue-oasys-with-transitions-light-intelligent-technology-contact-lenses/2479693/Johnson & Johnson Vision announced that data from two new studies on the visual effects of photochromic contact lenses were presented at the 2018 American Academy of Optometry Annual Meeting in San Antonio. These are the first scientific presentations focused on photochromic contact lens tech
- Oxurion Supporting Prevent Blindness Sight-Saving Programs for Those with Diabeteshttps://modernod.com/news/oxurion-supporting-prevent-blindness-sight-saving-programs-for-those-with-diabetes/2479709/To help support the fight against vision loss and blindness due to diabetes, Oxurion has partnered with Prevent Blindness. During the Diabetic Eye Disease Awareness Month in November, Oxurion will help Prevent Blindness promote awareness and education of the damaging effects that diabetes may hav
- Bausch + Lomb to Launch First-in-Class Surgical Support Applications for Stellaris Elite on IBM Cloudhttps://modernod.com/news/bausch-lomb-to-launch-first-in-class-surgical-support-applications-for-stellaris-elite-on-ibm-cloud/2479752/Bausch + Lomb and IBM announced the launch of the new eyeTELLIGENCE applications which will run on the IBM Cloud to help eye surgeons and surgical facilities work more efficiently using Stellaris Elite vision enhancement systems. The companies built the eyeTELLIGENCE applications to deliver surge